Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

overall survival was 9.7 months and that 12 of the 41 evaluable patients are currently alive. No incidences of rash were noted and results were reported to be comparable to intense chemotherapy and radiotherapy. Quality of life was reported as excellent when compared with intensive chemotherapy. Current and planned studies will expand the use of nimotuzumab from the pediatric population to adults with high grade brain tumors.

"Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth

factor receptor (EGFR) monoclonal antibody (MAb), in patients with

unresectable squamous cell carcinoma of the head and neck (SCCHN): A

SENDO Foundation study" (Abstract number 6070): Ten patients with advanced SCCHN, unsuitable for chemo-radiotherapy, were enrolled in a single center phase Ib clinical trial, where they received eight weekly infusions of nimotuzumab at two dose levels: 200mg and 400mg. Paired biopsies were taken from skin and primary tumors, before and 1 week after first infusion.

Nimotuzumab was well tolerated and there was no evidence of skin rash in any of the treated patients. Objective Response was achieved in 80% of patients (2 Complete Responses, 6 Partial Responses) and median survival time was 7.2 months. Results also demonstrated that after a short period of exposure, nimotuzumab as a single agent inhibited EGFR phosphorylation and this was accompanied by a trend towards molecular downstream effects consistent with the expected biological effects of EGFR targeting. The absence of inflammatory skin reaction might be linked to the lack of skin toxicity by the drug.

In addition, YM BioSciences presented data, described in a separate press release issued today by the Company, based on the following poster:
"Preliminary results of an escalating dose phase I clinical trial of the

anti-EGFR monoclonal antibody nimotuzumab in combination with external

radiotherapy in patients diagnosed
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Mature Biotech Outlook 2015: New Therapy Ventures ... offering. All biotech companies - Gilead ... in past year, have given a positive return and ... have been able to select therapy/niche indication where the ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The next ... have received the CE mark (European) approval. The CE ... Free Trade Association (EFTA) and the European Union. Following ... now been granted to implants supplied by the Turkey-based ... conditions. , Osimplant's Cervical Expandable Bladed HA PEEK ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... March 04, 2015 USDM Life ... the life sciences industry, hired David Blewitt ... Cloud Compliance Services and Solutions at USDM Life ... based applications while maintaining compliance with government regulations worldwide. ... been an accomplished life sciences regulatory and IS compliance ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... crowd who is proud to announce their compulsive habit of ... job classifieds. , ,Don't get me wrong. I don't spend ... communication skills" and the ever popular "outstanding communication skills." I ... it happens to be my first day on a new ...
... Milwaukee Rockwell Automation Inc. has increased ... 22.5 cents per share, up from 16.5 cents, ... Nosbusch said the change reflected strong earnings and ... ,Rockwell makes control and automation systems for industrial ...
... building relationships that will carry into your personal and professional ... on networking just for your employer. , ,The relationships you ... with you from job to job. Treat every relationship you ... will find it valuable to have some of these people ...
Cached Biology Technology:Is IT leadership a position or an attitude? 2Is IT leadership a position or an attitude? 3Networking for your employer is great for building your personal Rolodex 2Networking for your employer is great for building your personal Rolodex 3
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... include understanding new evidence for rock pulverization by catastrophic ... examples of active arc-continent collision in Taiwan; discovery and ... Earth, located in Japan; the puzzling record of the ... last 500 million years; and a possible refutation of ...
... the tropical fish known as swordtail characins have flag-like sex ... fishing rod would. What,s more, a study reported online on ... publication, shows just what any good fly-fisherman would know: Lures ... often eat. For some characins in the study, that means ...
... . , It is not unusual for babies to ... of the heart in the embryo is a process which is ... Planck Institute for Heart and Lung Research in Bad Nauheim have ... regulating the function of stem cells in the heart. As a ...
Cached Biology News:Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 2Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 3Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 4Male sex ornaments are fishing lures, literally 2Finished heart switches stem cells off 2Finished heart switches stem cells off 3
...
... PCR specificity *High PCR specificity ... with unique QIAGEN PCR Buffer ... by the stringent built-in hot start ... Mix and simple reaction setup at ...
... Nuclear matrix proteins (NMPs) make up the internal ... with such functions as DNA replication, RNA synthesis, ... has been shown to be highly insoluble ... cell death releases soluble nuclear matrix proteins that ...
Request Info...
Biology Products: